ocrelizumab and hyaluronidase
ocrelizumab and hyaluronidase is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including Ocrevus Zunovo. Available dosage form: injection, solution.
Drug Details
- Generic Name
- ocrelizumab and hyaluronidase
- Brand Names
- Ocrevus Zunovo
- Application Number
- BLA761371
- Sponsor
- Genentech, Inc.
- NDC Codes
- 1
- Dosage Forms
- INJECTION, SOLUTION
- Routes
- SUBCUTANEOUS
- Active Ingredients
- OCRELIZUMAB, HYALURONIDASE (HUMAN RECOMBINANT)
Indications and Usage
1 INDICATIONS AND USAGE OCREVUS ZUNOVO is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults OCREVUS ZUNOVO is a CD20-directed cytolytic antibody indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 ) Primary progressive MS, in adults ( 1 )